ORPOF (OSE Immunotherapeutics) YoY EPS Growth: -188.16% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORPOF OSE Immunotherapeutics SA ORPOF
41 GF Score
Price $4.43
GF Value $1.99
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics YoY EPS Growth?

OSE Immunotherapeutics ORPOF 41 YoY EPS Growth is -188.16% as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $1.99. The stock has 6 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. OSE Immunotherapeutics's YoY EPS Growth for the quarter that ended in Dec. 2025 was -188.16%.

OSE Immunotherapeutics's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was $-2.78.

OSE Immunotherapeutics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics YoY EPS Growth Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.53 3.24 -26.55 218.80 -229.43

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.56 452.53 -63.50 -67.91 -188.16
ORPOF
41GF Score
OSE Immunotherapeutics SA ORPOF
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

OSE Immunotherapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-1.979-1.529)/ | 1.529 |
=-229.43 %

OSE Immunotherapeutics's YoY EPS Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EPS Growth (Q: Dec. 2025 )
=(Earnings per Share (Diluted) (Q: Dec. 2025 )-Earnings per Share (Diluted) (Q: Dec. 2024 )) / | Earnings per Share (Diluted) (Q: Dec. 2024 )) |
=(-2.775--0.963)/ | -0.963 |
=-188.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -188.16% mean?
OSE Immunotherapeutics (ORPOF) has a YoY EPS Growth of -188.16% as of Dec. 2025. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for OSE Immunotherapeutics and its competitors.
Is OSE Immunotherapeutics' YoY EPS Growth too high?
OSE Immunotherapeutics' current YoY EPS Growth is -188.16%. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' YoY EPS Growth compare to VRTX and REGN?
OSE Immunotherapeutics' YoY EPS Growth of -188.16% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current YoY EPS Growth is -188.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
OSE Immunotherapeutics (ORPOF) has a current YoY EPS Growth of -188.16%. The stock's GF Value™ is $1.99, compared to a current price of $4.43 — trading 122.6% above its estimated fair value. The current YoY EPS Growth is -188.16%. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current YoY EPS Growth is -188.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 122.6% above its estimated GF Value™ of $1.99.

Key valuation signals for ORPOF:

  • YoY EPS Growth: -188.16%
  • GF Value™: $1.99 vs. price of $4.43 (122.6% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score

Get the complete analysis for ORPOF

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$1.99
GF Value